TX_GSK923295A
FIRST_LINE_TREATMENT
SPECIFIC_DX_AT_ACQUISITION_MDSMPN
TREATMENT_PALLIATIVE_RADIATION
TX_MK-2206
TX_AZD-6244
METASTASECTOMY_SITE
INITIAL_DIAGNOSIS_OF_RECURRENT_TUMORS
PRETREATED
CANCER_IDENTIFICATION_MIDLC
X2YR_VEGF_INHIBITOR
LOCATION_RECURRED
CLAUDIN_SUBTYPE
AGE_IN_DAYS
PRIOR_LINES
OFF_TREATMENT
TX_VINCRISTINE
TX_KPT-330
TX_SVV-001
PRD_RADIATION_SURGERY
CHEMO_CONCURRENT_TYPE_OTHER
ANY_LINE_IMMUNO
AGE_AT_DIAGNOSIS_GROUP
COUNTRY
PRIMARY_MELANOMA_SKIN_TYPE
TX_TB-403
TARGETED_MOLECULAR_THERAPY
CUMULATIVE_TREATMENT_TYPE_COUNT
TX_CBL0137
BREAST_CANCER_SUBTYPE
LFS_STATUS
TREATMENT_TYPE
TX_ACTINOMYCIN D
TESTES_SITE_OF_RELAPSE
EPINEPHRINE
TX_NSC750854
RT_TX_REASON_NOT_COMPLETED
TX_XL147
DIAGNOSIS_AT_INCLUSION
AGE_AT_RADIATION_STOP
TX_APLIDIN
LINEAGE_SUB_SUBTYPE
PATHOLOGY_CLASSIFICATION
SUBTYPE_DETAILS
DMETS_DX_MALE_GENITAL
POST_SAMPLE_CHEMOTHERAPY
PRIMARY_DIAGNOSIS
TX_MM-141
THERAPIES
OTHER_HYSTERECTOMY_TYPE
TUMOR_SAMPLE_PROCUREMENT_COUNTRY
DOMINANT_HISTOLOGICAL_SUBTYPE
TOPO_II_TX
ADJUVANT_TARGETED
TX_PIXANTRONE
NUMBER_OF_CYCLES_PEMBROLIZUMAB
AGE_AT_DEATH
PREDOM_HISTO_SUBTYPE
AGE_AT_SCC
AGE_AT_METS
SPECIFIC_DIAGNOSIS_AT_ACQUISITION
TERT_PLATINUM_TX
ADC_THERAPY
PRD_HORMONE_THERAPY
TX_INDUCTION_COURSES_INDICATOR
CANCER.TYPE
TREATMENT_DETAIL_BEFORE_PDX
PERSON_NEOPLASM_CANCER_STATUS
NEOADJUVANT_THERAPY
PRE_SAMPLE_IMMUNOTHERAPY
RADIATION_SITE
RADIO_THERAPY
NUM_LINES_IODINE
NUCLEOSIDE_TX
TYPE
HIST_SUBTYPE2
CNS_DISEASE
HISTOLOGY_SUBTYPE
TERT_OXALIPLATIN_TX
TOPO_I_TX
FOURTH_LINE
TUMOR_SITE_DETAIL
NEOADJ_CHEMOCYCLES
COMPLETED_TOTAL_RADIATION_DOSE
IO_THERAPY
TUMOR_TISSUE_SITE
TOTAL_CYCLES_NUM_NEOADJUVANT_ADJUVANT
MONTHS_ON_TREATMENT
IO_DRUG
WEEKS_ON_STUDY
NEOADJUVANT
TX_BAL101553
NEOADJ_CHEMOAGENT
SURGICAL_APPROACH_AT_DIAGNOSIS
DIAGNOSIS_CANCER_LOC_LUNG
THIRD_LINE
OS_NEO_STATUS
AGE_TESTING_YEARS
PHARM_TX_MITOTANE_INDICATOR
CHEMOTHERAPY+IMMUNOTHERAPY
DIAGNOSIS_CANCER_LOC_BREAST
ANCESTRY_PRIMARY
SURGERY_ADVANCED_DISEASE
REASON_FOR_TX_DISCONTINUATION
MULTIPLE_TUMOR_LOCATIONS
SALVAGE_CHEMO
ALTERNATE_THERAPY_OTHER
MCRC_TYPE
ADMINISTRATION_OF_DRUG_WEEKS
POST_MAPK_TX
FORMULATION
RADIOTHERAPY_FRACTIONS
TMZ_TREATMENT
SURGERY_INDICATION
HISTOLOGICAL_SUBTYPE
X2YR_ANTIHER2
MEDICATION
ANTHRACYCLINE_TX
TUMOR_LATERALITY
VITAL_STATUS
DSS_STATUS
TX_AZD1480
AGE_AT_SEQUENCING
PREDOMINANT_HISTOLOGIC_SUBTYPE
CANCER_TYPE_DETAILED
FOLIC_ACID_TX
ADJUVANT_HORMONE_THERAPY
SURGERY_TYPE
PRD_OTHER_THERAPY
TX_SETTING
TX_LENOLIDAMIDE
COMPLETED_RADIATION_DOSE
CARBOPLATIN_TX
SUBSEQUENT_RX
RT_TX_REASON_NOT_COMPLETED_OTHER
ONGOING_TREATMENT
SURVIVAL_STATUS
AGE_AT_EVIDENCE_OF_METS
BIOPSY_SITE
METASTATIC_SITE
PAM50_SUBTYPE
CHEMO_REGIMEN_CATEGORY
PROCEDURE
ALL_TX_AT_MSK
INTEGRATED_PHENOTYPE
DEFINITIVE_SURGICAL_PROCEDURE
RADIATION_THERAPY_XRT_TYPE
IO_REGIMEN_MONOTHERAPY_VS_COMBINATION
PREVIOUS_TREATMENT
DIAGNOSIS_CANCER_LOC_CHEST_WALL
MUTATION_PHENOTYPE
ENDOCRINE_THERAPY
ADJ_XRT
TERT_TARGETED_TX
CURRENT_REGIMEN
ADJUVANT_IMMUNOTHERAPY
RADIATION_THERAPY
TUMOR_LOCATION_CONDENSED
R_CHOP_LIKE_CHEMO
AGE_AT_DOS_BX
ALKYLATING_CHEMOTHERAPY
TERT_OTHER_CYTOTOXIC_TX
X2YR_CAPECITABINE
INFERRED_ETHNICITY
TUMOR_LEVEL
ORAL_CONTRACEPTION
TREATMENT_AT_MSK
TESTICULAR_INVOLVEMENT
STATUS
PRD_RADIATION
TESTIS_TUMOR_MACROEXTENT
LOCALIZED_TUMOR
ESOPHAGEAL_TUMOR_LOCATION_CENTERED
NONINVASIVE_BLADDER_CA_TX_TYPE
TREATMENT_ONGOING
TUMOR_SUPERSITE
PRE_SAMPLE_TX
ADENOCARCINOMA_SUBTYPE_WHO2015
TX_CGC(PG)-11047
ADJUVANT_CT
X2YR_TAXANE
DISEASE_MULTIFOCAL_INDICATOR
AGE_AT_INITIAL_PATHOLOGIC_DIAGNOSIS
SAMPLE_CLASS
TUMOR_SURGERY_NUMBER
AGE_AT_CHEMOTHERAPY_STOP
SUBTYPE_GROUP
POST_SAMPLE_IMMUNOTHERAPY
SEX
PFS_STATUS_SORAFENIB_TREATMENT
IFN_TX_90_DAYS_PRIOR_TO_RESECTION
DRUG_LAST_ADMIN
DURATION_OF_THERAPY_WEEKS
TX_HGS-ETR1
TUMOR_MEGASITE
TREATMENT_GROUP
SPECIAL_HISTOLOGY
ANYTIME_CANCER_LOC_OVARY
BRACHYTHERAPY_TYPE_OTHER
PRIOR_TREATMENT
PRIMARY_TUMOR_LOCATION
OTHER_CONCURRENT_THERAPY
PD1_INHIBITOR_CONCURRENTLY_WITH_DC_VAX
X2YR_ANTHRACYCLINE
PRD_OTHER_CANCER_RADIATION
LINEAGE_SUBTYPE
PRE_SAMPLE_XRT
LOCATION_LUNG_PARENCHYMA
HISTOLOGICAL_TYPE
CHEMO_OTHER
DISEASE_ONTOLOGY
TERT_TOPO_I_INH_TX
AGE_AT_MET
ANY_LINE_CHEMO
DETAILED_PRIMARY_SITE
DIAGNOSIS_CANCER_LOC_OVARY
TERT_MICROTUBULE_TX
NEOADJ_CHEMO
TX_GS-9820
SPECIMEN_TYPE
TX_ABT-263
RADIATION
PRD_RACE
ADJUVANT_CYCLES_NUM
RADIATION_OTHER
AGE_AT_SAMPLING
CANCER_TYPE
PRETREATMENT_HISTORY
TX_CYCLOPHOSPHAMIDE
RADIATION_DOSE_PELVIC_NODES_PRIMARY_TUMOR.
TAXANE_TX
TYPE_INDUCTION_TREATMENT
GASTRIC_CLASSIFICATION
DRUG_TYPE
TX_MK-8242
ANATOMICAL_SUBTYPE
HYSTERECTOMY_TYPE
TX_STA9090 (GANETESPIB)
CYCLES_COMPLETED
PRIOR_MAPK_TX
TREATMENT_RADIATION
POSTOPERATIVE_TX
SYSTEMIC_THERAPY
TKI_TREATMENT
TARGETED_THERAPY
NOREPINEPHRINE
TERT_ANTIMETABOLITE_TX
PATIENT_AGE_AT_DIAGNOSIS
TX_JNJ26481585
TREATMENT_PRIOR_TO_RESECTION
PRIMARY_SITE_PATIENT
TUMOR_TISSUE_SITE_PATIENT
TERT_ANTHRACYCLINE_TX
PRIMARY_RADIATION_THERAPY
THERAPY
FATTY_LIVER_DISEASE
CUMULATIVE_CHEMO
SYSTEMIC_CHEMO
NEOADJUVANT_TREATMENT_DETAILS
DISEASE_CODE
PD1_INHIBITOR
METASTATIC_RADIATION_THERAPY
CISPLATIN_TX
STEROIDS_WHEN_STARTED_PD1_INHIBITOR
NUM_LINES_HORMONE
HISTORY_MENOPAUSAL_HORMONE_THERAPY
CUMULATIVE_TREATMENT_REGIMEN_COUNT
SALICYLATES
CUMULATIVE_TREATMENT_TYPES
BRACHYTHERAPY_TYPE
ETHNICITY_SELF_IDENTIFY
CRDB_PRIOR_RX
SURGERY_AT_DX
INVASIVE_CARCINOMA_DX_AGE
COUNTRY_OF_ORIGIN
TX_LOCATION
TX_JNJ26854165
X2YR_ALKYLATING_AGENT
CANCER_SUBTYPE_CURATED
NUM_LINES_IMMUNO
IMMUNOTHERAPY
CHEMO_CONCURRENT_REASON_NOT_OTHER
PROTOCOL_AND_TREATMENT_ARM
SURGERY_FOR_POSITIVE_MARGINS
RADIATION_TREATMENT_ADJUVANT
TX_BMN-673
CHRONIC_HEPATITIS_ANY_TYPE
PATHOLOGICAL_DIAGNOSIS
ADJUVANT_XRT
PD1_INHIBITOR_CONCURRENTLY_WITH_NOVO-TTF
DOPAMINE
LOCATION
ADJUVANT_RADIATION_THERAPY
TX_RO4929097
TREATMENT_CHANGED
TX_SU11248
DOSE_OF_PEMBROLIZUMAB_PER_INJECTION (MG/KG)
TX_TOPOTECAN
STREOIDS_DURING_PD1_INHIBITOR
CRT_CHEMOAGENT
TX_RG7112
NUMBER_OF_CYCLES_PLATINUM
INTESTINAL_TYPE_SUBCLASS
ALPELISIB_DOSE
RADIOTHERAPY_TX
ADJUVANT
IMMUNOSUPPRESSION
HEPATECTOMY
AGE_AT_DIAGNOSIS
TX_VS-4718
CHEMO_OTHER_CYCLES
NUMBER_OF_PD1_INHIBITOR_INJECTIONS
NUM_PRIOR_THERAPIES
X2YR_TAMOXIFEN
DRUG_START
ADJUVANT_THERAPY
DIAGNOSIS_CANCER_LOC_SKIN
AGE_AT_RADIATION_START
NUM_LINES_CHEMO
WHO_CLASSIFICATION
PRIMARY_TUMOR_LOCALIZATION_TYPE
ANY_LINE_NTRK
TX_PR-104
FIRST_LINE_THERAPY
SOURCE_TYPE
NUMBER_OF_CYCLES_FLUORO-PYRIMIDINE
ADC+IMMUNOTHERAPY
GENDER
PD1_INHIBITOR_CONCURRENTLY_WITH_BCNU/CCNU
INDUCTION
PD1_INHIBITOR_CONCURRENTLY_WITH_TEMODAR
MORPHOLOGY_SUBTYPE
ADJUVANT_CHEMO
STEROIDS_GT_10MG_DAILY
TX_SGN-CD19A
ETHNICITY
FIRSTLINE_CHEMO_GROUP
DIAGNOSIS_CANCER_BONE
MICROTUBULE_TX
TX_19D12
LINES_OF_TX
AGE_AT_SEQ_REPORTED_YEARS
CURRENT_CYCLE
RADADJUVANTRX
CYTOTOXIC_TREATMENT
ANTIMETABOLITE_TX
TX_BMS-354825
SUBTYPE
RECEIVED_TARGETED_TX
PRD_TREATED_AT_ENROLLMENT
NUM_LINES_NTRK
AGE_AT_INITIAL_DIAGNOSIS
TX_E7438/EPZ6438
RADIATION_OR_CHEMOTHERAPY
ALKYLATING_TX
NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION
ANY_LINE_TARGETED
SURGERY_DATE_RELATIVE_TO_DX_MONTHS
SURGICAL_PROCEDURE_FIRST
AGE
TERT_CARBOLATIN_TX
CHEMO_CONCURRENT_TYPE
TREATMENT_CHEMOTHERAPY
PRD_CHEMOTHERAPY
AGE_AT_RESECTION
DURATION_OF_INDUCTION_TREATMENT
ANY_THERAPY_2YRS
DETAILS_FIRST_LINE_COMMENTS
TX_SB-715992
PRIOR_THERAPY
CHEMO_TX
ALKYLATING_AGENT
TX_STF-118804
AGE_START_IO
AGE_AT_PROCUREMENT
PRIOR_TX_TO_IMPACT_SAMPLE
PRD_HISPANIC
RECEIVED_IO_AFTER_1ST_LINE
CHEMO_CONCURRENT_FRACTIONS_TOTAL
PHARM_TX_MITOTANE_FOR_MACRO_DISEASE
CALC_TREATMENT_NAIVE
AGE_AT_SAMPLE_COLLECTION
DISEASE_EXTENT
NUMBER_OF_LINES_OF_TREATMENT_FOR_MET_DISEASE
2L_TREATMENT
TUMOR_SITE_CURATED
IPCHEMO_FIRST_CRS
AGE_AT_SPECIMEN_ACQUISITION
WHO_CLASS
DX_ORG_INST
PARTICIPANT_COUNTRY
PRD_SURGERY
DIAGNOSIS_CANCER_LOC_PLEURAL_EFFUSION
SPECIFIC_DX_AT_INCLUSION
FIRST_SURGICAL_PROCEDURE_OTHER
HISTOLOGY_DIAGNOSIS
PRIMARY_SURGERY
FAMILY_HISTORY_TESTICULAR_CANCER
CHEMO_DETAILS
METS_SITES_AT_METS_DX_OVARY
OS_STATUS_SORAFENIB
RADIATION_THERAPY_DOSE_PARAAORTIC_NODES
DRUG
TX_CABOZANTINIB (XL-148)
TX_MLN4924
PRE_SAMPLE_TARGETED
TREATMENT_HORMONE_THERAPY
TX_LAPATINIB
TX_SCH 727965
DIAGNOSIS_CANCER_LOC_OTHER_LN
TX_MAINTENANCE_COURSES_INDICATOR
TX_CYTARABINE
TX_MLN8237
TUMOR_LOCATION
HISTOLOGICAL_DIAGNOSIS
TARGET_THERAPY
CUMULATIVE_TREATMENT_STAGE_COUNT
MARGINS_INVOLVED_HYSTERECTOMY
TREATED_WITH_ICI
SURGERY NUMBER
CYTOTOXIC_TX
TREATMENT_SCHEDULE
STEROIDS
DIAGNOSIS_CANCER_LOC_LIVER
TISSUE_SITE
CRDB_TREATMENT_END_DAYS
DRUG_AND_DOSE_STEROID_DURING_PD1
POAR_COMBINED_CTLA_PD1
DOT_MONTHS
INITIAL_TREATMENT
INITIAL_DIAGNOSIS_TYPE
TX_REG
FIRST_LINE_MET_TX
TX_RAPAMYCIN
TREATMENT_STATUS
ADJUVANT_CHEMOTHERAPY
HISTORY_IONIZING_RT_TO_HEAD
HISTORY_IMMUNOSUPPRESSIVE_TX_OTHER
TUMOR_SITE_SAMPLE
PRIOR_LINES_OF_THERAPY
TERT_TAXANE_TX
ESOPHAGEAL_TUMOR_LOCATION_INVOLVED
IO_LINE
CLINICAL_STATUS_AT_COLLECTION_EVENT
GYN_DIAGNOSIS_HISTOLOGY
TX_ERIBULIN
DIAGNOSIS AGE
CONCURRENT_CHEMOTHERAPY
DOSE_MG_DAY_STEROID_PD1_START
SUBTYPE_ABBREVIATION
CANCER_IDENTIFICATION_IDC
OXALIPLATIN_TX
TX_SGI-1776
RADIOTHERAPY
TX_GSK690693
CYTOLOGICAL_PHENOTYPE
DIAGNOSIS_CANCER_LOC_BRAIN
SORAFENIB_TREATMENT
TX_LY 2606368
TUMOR_SUBSITE
EXTRANODAL_DISEASE
CYCLES_ON_THERAPY
MDSMPN_DIAGNOSIS_AT_ACQUISITION
NGS_PRIOR_THERAPY
TISSUE_TYPE
CHEMOTHERAPY_AGENTS
TERT_CYTOTOXIC_TX
SURGERY_PROCEDURE
INTERFERON_ALPHA
TREATMENT_PRIOR_TO_SURGERY_INDICATOR
TX_RUXOLITINIB
TX_CDX-011 (GLEMBATUMUMAB)
DOSE_MG_DAY_STEROID_DURING_PD1
TARGETED_TX
IMMUNE_TREATMENT
ALPELISIB_SCHEDULING
CHEMO_CONCURRENT_COURSE
BREAST_SURGERY
RT_TX_TOTAL_DOSE_TO_PELVIS
ADJUVANT_CHEMO_REGIMEN
X2YR_CDK46
HISTORY_NEOADJUVANT_MEDICATION
ABLATION_EMBOLIZATION_TX_ADJUVANT
RACE_CATEGORY
AGENT
PRE_SAMPLE_CHEMOTHERAPY
TIMING_OTHER_NOTES
CUMULATIVE_TREATMENT_REGIMENS
AGE_AT_PD1
TX_90DAYS_POST_RESECTION
DISEASE
SPECIFIC_TUMOR_LOCATION
BIRTH_COUNTRY
NUM_LINES_TARGETED
PFS_STATUS_IO
ANY_LINE_IODINE
HISTORY_NEOADJUVANT_STEROID_TX
DETAILED_CANCER_TYPE
TX_SAHA
CHEMOTHERAPY_PRIOR_SAMPLE_ACQUIRED
DURATION_OF_THERAPY_DAYS
DFS_STATUS
LAST_STATUS
AGE_D
TISSUE_SITE_OF_DERIVATION
AGE_GROUP
TX_SAR3419
SPECIFIC_DIAGNOSIS_AT_INCLUSION
CHEMO_CONCURRENT_REASON_NOT_GIVEN
DIAGNOSIS_CANCER_LOC_AXILLARY_LN
NEOADJUVANT_IMMUNOTHERAPY
INITIAL_RX
HYPERTENSION_DIAGNOSIS
CERVIX_SUV_RESULTS
ANY_LINE_HORMONE
TREATMENT_PROSTATECTOMY
HISTORY_REFLUX_DISEASE_TREATMENT
NEOADJUVANT_CHEMOTHERAPY
TERT_CISPLATIN_TX
AGE_AT_DX
ORIGINAL_DIAGNOSIS_AT_IMPLANT
AGE_AT_DERIVATION
OS_STATUS_IO
TYPE_OF_SURGERY
HISTORY_HORMONAL_CONTRACEPTIVES_USE
PRIOR_ADJUVANT_CHEMO
CRDB_SURVIVAL_STATUS
XRT_TX
TX_PCI-32765
RACE_CATEGORIZED
PHARMACEUTICAL_TX_ADJUVANT
MDS_TYPE
FIRST_THERAPY
BRACHYTHERAPY_TOTAL_DOSE_POINT_A
TYPE_REFINED
TX_TAK-701
POST_SAMPLE_TX
RADIATION_TYPE_OTHER
PRIOR_MALIGNANCY_RADIATION_TX
CHEMO_CONCURRENT_DOSE
MOST_RECENT_TREATMENT_TYPE
AGE_AT_TCGA_SPECIMEN
TERT_TOPO_II_INH_TX
ICI
TMZ_CYCLES
TX_EC1456
TYPE_INDUCTION_TX
RACE
TX_ABT-199
HISTORY_OF_UNDESCENDED_TESTIS
DOSE_OF_RE-IRRADIATION
HISTORY_NEOADJUVANT_TX_TYPE
TX_BORTEZOMIB
LOCALIZED_VS_METS_AT_DX
KINASE_INHIBITOR
DIABETES_DIAGNOSIS_INDICATOR
TUMOR_SITE
HISPANIC
PRIOR_INTRAVESICAL_CHEMOTHERAPY
TX_TRISENOX(ATO)
AGE_YRS
NEOADJUVANT_XRT
OS_FROM_PD1I_STATUS
TREATMENT
PRIOR_SYSTEMIC_THERAPIES
TX_CPX351
CHEMOTHERAPY
OTHER_CYTOTOXIC_TX
TX_AZD8055
IHC_SUBTYPE
LAUREN_CLASS
NUMBER_OF_CYCLES_TRASTUZUMAB
CHEMO_CYCLES
TX_BET_PRI_MET_SAMPLE_COLLECTION
TX_FENRETINIDE
FIFTH_LINE
TERT_IO_TX
RADIATION_DOSE
POST_SAMPLE_XRT
AGE_AT_CHEMOTHERAPY_START
SUBTYPE_CONSENSUS
PATIENT_TO_UNDERGO_SURGERY
PLATINUM_OS_STATUS
CHEMO_FIRST_LINE
TX_BMS-754807
RADIATION_TYPE
TX_ABRAXANE
ON_TREATMENT
PRD_PROSTATECTOMY
PD1_INHIBITOR_CONCURRENTLY_WITH_RE-IRRADIATION
CHEMOTHERAPY_TYPE
3L_TREATMENT
TX_CISPLATIN
PD1_INHIBITOR_STARTED_FOR_PD
curated_cancer_type
YEAR_OF_SURGERY
OS_STATUS
TX_17-DMAG
DX_AT_INCLUSION
SAMPLE_TYPE
PD1_INHIBITOR_WITH_CELECOXIB
MAINTENANCE_TX
PRIMARY_SITE
PD1_INHIBITOR_WITH_IMATINIB
AGE_RESECTED
HIST_SUBTYPE1
TX_GENZ-644282
TRANSPLANT_TYPE
TX_BI6727 (VOLASERTIB)
PHARM_TX_MITOTANE_ADJUVANT
TX_INK128-1110-028
TX_CX-5461 (POL1)
TX_LINE
METASTASECTOMY
IO_TX
WEEKS_ON_TREATMENT
RESIDUAL_NODAL_DISEASE
THERAPY_PRIOR_TO_DERIVATION
TUMOR_TISSUE_ORIGIN
METS_SITES_AT_METS_ABST_OVARY
TOTAL_TIME_PERIOD_MONTHS
TX_AZD-2171
AGE_AT_SEQ_REPORT
NEOADJUVANT_TARGETED
NEOADJUVANT_CHEMO
HISTORY_NEOADJUVANT_TRTYN
PLATINUM_TX
TREATMENT_CATEGORY
HER2_VITAL_STATUS
PREVIOUS_MAPKI
SECOND_LINE_TC_OR_SURGERY
ANDROGEN_DEPRIVATION_THERAPY
DMETS_DX_FEMALE_GENITAL
INTRAVESICAL_TREATMENT
HORMONE_THERAPY
TX_PF-03084014
ALTERNATE_THERAPY
CUMULATIVE_TREATMENT_STAGES
X2YR_FULVESTRANT
CANCER_IDENTIFICATION_ILC
SYSTEMIC_TREATMENT
NUM_LINES
TERT_ALKYLATING_TX
X2YR_AIS
TX_SORAFENIB
HAD_SURGERY
DMETS_DX_OVARY
RFS_STATUS
PROCEDURE_TYPE
COUNTRY_OF_PROCUREMENT
MOST_RECENT_TREATMENT_DURATION
HISTORY_IMMUNOSUPPRESIVE_DX
REPORTED_ETHNICITY
PD1_INHIBITOR_DRUG
PRIOR_TREATMENT_OF_CYTOTOXIC_CHEMOTHERAPY
GYN_DIAGNOSIS_CHEMO_INTENT_DESCRIPTION
PRIMARY_TYPE
PD1_INHIBITOR_CONCURRENTLY_WITH_BEV
DIAGNOSIS
DX_TYPE
LINES_OF_TX_PRIOR_IMPACT
TX_IMC-A12
SURGERY_FOR_POSITIVE_MARGINS_OTHER
ADJUVANT_TX
PRIORRADIATIONFOROTHERCANCER
POST_SAMPLE_TARGETED
SURGERY
TX_TL32711
UV_RATE
TREATMENT_DETAILS
TREATMENT_ARM
INCIDENTAL_PROSTATE_CANCER
OS_STATUS_DMT
